News
Canaccord Genuity Maintains Buy on Quanterix, Lowers Price Target to $25
29 Apr 24
News, Price Target, Analyst Ratings
Quanterix Reveals Specific Partnership Path For Laboratories Interested In Offering Tau Based Research And Diagnostic Testing Services
21 Mar 24
News
Scotiabank Maintains Sector Outperform on Quanterix, Raises Price Target to $32
4 Mar 24
News, Price Target, Analyst Ratings
Quanterix Granted Breakthrough Device Designation From U.S. FDA For Blood-Based p-Tau 217 Test For Alzheimer's Disease
4 Mar 24
Biotech, News, FDA, General
Earnings Scheduled For February 29, 2024
29 Feb 24
Earnings
Earnings Preview: Quanterix
28 Feb 24
Earnings
Earnings Scheduled For February 27, 2024
27 Feb 24
Earnings
Reported Earlier, Quanterix Reaffirmed Its 2023 Guidance, Expects GAAP Gross Margin In The High 50s Percent, And Non-GAAP Gross Margin To Be Around 50%; Q4 Earnings Call Rescheduled
27 Feb 24
News
A Preview Of Quanterix's Earnings
26 Feb 24
Earnings
Quanterix Announces First Collaborations With Five Health Networks To Aid The Diagnosis And Clinical Management Of Individuals With Alzheimer's Disease
26 Feb 24
Biotech, News, General
Earnings Scheduled For February 26, 2024
26 Feb 24
Earnings
Earnings Outlook For Quanterix
23 Feb 24
Earnings
Press releases
Quanterix Outlines Partner Path With Labs to Expedite Building Global Alzheimer's Disease Testing Infrastructure
21 Mar 24
Press Releases
Quanterix Granted Breakthrough Device Designation from U.S. FDA for Blood-Based p-Tau 217 Test for Alzheimer's Disease
4 Mar 24
Press Releases
Quanterix Releases Operating Results for Fourth Quarter and Full Year 2023
29 Feb 24
Press Releases
Quanterix Reschedules Q4 and Full Year 2023 Earnings Conference Call; Reaffirms 2023 Guidance
26 Feb 24
Press Releases
Quanterix to Present at Cowen's 44th Annual Health Care Conference
23 Feb 24
Press Releases
Quanterix Fourth Quarter Earnings and Full Year 2023 Financial Results Conference Call
16 Feb 24
Press Releases